What is TherapeuticsMD, Inc.'s earnings per share (EPS)?

TherapeuticsMD, Inc. (TXMD) reported diluted earnings per share of -$0.05 for fiscal year 2025. This represents a 73.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

TherapeuticsMD, Inc. (TXMD) Financials

TXMD

Trailing 12 months to June 30, 2026

Revenue $3.3M +27.8% YoY

Net Income -$217K +52.7% YoY

EPS (Diluted) -$0.02 +50.0% YoY

Operating Cash Flow $3.1M +201.9% YoY

Market Cap $23.8M as of Oct 10, 2026

Price / Sales 7.3x on $3.3M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.9x on $27.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TXMD SEC filings page.

TherapeuticsMD, Inc. (TXMD) reported $3.3M in revenue over the twelve months to Jun 30, 2026, up 27.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TXMD FY2025 2026-10-03

The business is shrinking toward a smaller, less liability-funded operation while losses narrow and operating cash flow turns positive.

Earnings quality has changed sharply: FY2025 reported a net loss of $569K, versus a FY2022 net profit of $112.0M. Yet operating cash flow remained positive at $2.5M in FY2025, so the latest loss is not currently accompanied by operating cash consumption; that gap points to non-cash or working-capital effects rather than profitable operations.

The current ratio rose from 1.2x in FY2022 to 3.0x in FY2025, indicating short-term obligations became easier to cover on reported balance-sheet measures. Debt-to-equity also fell from 1.6x to 0.4x, consistent with less reliance on liabilities as the balance sheet contracted.

FY2025 revenue was $3.0M, while the operating margin remained -145.3%, so positive cash flow should not be read as operating profitability. The combination suggests a very small revenue base alongside an expense structure still larger than current sales.

Financial Health Signals

Financial Health Score 63/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of TherapeuticsMD, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

TherapeuticsMD, Inc. held $7.5M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $2.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and TherapeuticsMD, Inc. scores 86/100 among other emerging companies.

Dilution

TherapeuticsMD, Inc. had 12M shares outstanding at the end of fiscal year 2025, against 12M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and TherapeuticsMD, Inc. scores 72/100 among other emerging companies.

R&D Intensity

Not available for TherapeuticsMD, Inc., and counted as zero in the overall score.

Revenue Progress

TherapeuticsMD, Inc. reported revenue of $3.0M in fiscal year 2025, against $1.8M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and TherapeuticsMD, Inc. scores 80/100 among other emerging companies.

Burn Trend

TherapeuticsMD, Inc.'s operations generated $2.5M of cash in fiscal year 2025, against $1.2M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and TherapeuticsMD, Inc. scores 88/100 among other emerging companies.

Balance Sheet

TherapeuticsMD, Inc.'s cash, cash equivalents and investments came to $7.5M at the end of fiscal year 2025, against $10.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and TherapeuticsMD, Inc. scores 50/100 among other emerging companies.

Altman Z-Score Distress

-34.08

TherapeuticsMD, Inc. scores -34.08, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($23.8M) relative to total liabilities ($10.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/7

TherapeuticsMD, Inc. passes 6 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

TherapeuticsMD, Inc. reported a net loss of $569K while generating $2.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

TherapeuticsMD, Inc. reported an operating loss of $4.4M against $8K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$869K

YoY-8.7%

QoQ+20.0%

TherapeuticsMD, Inc. generated $869K in revenue in Q2 2026. This represents a decrease of 8.7% from the same quarter a year earlier. Against the prior quarter it is up 20.0%.

EBITDA

-$721K

YoY-20.4%

QoQ-14.6%

TherapeuticsMD, Inc.'s EBITDA was -$721K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.4% from the same quarter a year earlier. Against the prior quarter it is down 14.6%.

Net Income

$155K

YoY-71.9%

QoQ+63.2%

TherapeuticsMD, Inc. reported $155K in net income in Q2 2026. This represents a decrease of 71.9% from the same quarter a year earlier. Against the prior quarter it is up 63.2%.

EPS (Diluted)

$0.01

YoY-80.0%

TherapeuticsMD, Inc. earned $0.01 per diluted share (EPS) in Q2 2026. This represents a decrease of 80.0% from the same quarter a year earlier.

Cash & Balance Sheet

Cash & Debt

$9.2M

YoY+51.4%

QoQ+9.1%

5Y CAGR-39.3%

10Y CAGR-25.2%

TherapeuticsMD, Inc. held $9.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

12M

YoY0.0%

TherapeuticsMD, Inc. had 12M shares outstanding in Q2 2026. That is unchanged from the same quarter a year earlier.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Operating Margin

-93.9%

YoY-20.9pp

QoQ+6.0pp

TherapeuticsMD, Inc.'s operating margin was -93.9% in Q2 2026, reflecting core business profitability. This is down 20.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.0 percentage points.

Net Margin

17.8%

YoY-40.0pp

QoQ+4.7pp

TherapeuticsMD, Inc.'s net profit margin was 17.8% in Q2 2026, showing the share of revenue converted to profit. This is down 40.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.7 percentage points.

Return on Equity

0.6%

YoY-1.4pp

QoQ+0.2pp

TherapeuticsMD, Inc.'s ROE was 0.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Capital Allocation

None of these metrics is reported for Q2 2026.

TXMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TXMD quarterly income statement

Metric	TTM	FY2510-K/A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$3.3M	$3.0M+71.6%	$1.8M+35.3%	$1.3M-98.1%	$70.0M+2619.1%	$2.6M-96.0%	$64.9M+30.7%	$49.6M+208.4%	$16.1M-4.0%	$16.8M-13.3%	$19.4M-3.9%	$20.1M+34.1%	$15.0M+71.2%	$8.8M+129.8%	$3.8M+82.8%	$2.1M
Cost of Revenue	N/A	N/A	N/A	N/A	$1.4M-0.4%	$1.4M-91.2%	$16.0M+152.2%	$6.3M+131.4%	$2.7M+3.8%	$2.6M-37.0%	$4.2M-7.1%	$4.5M+22.7%	$3.7M+87.4%	$2.0M+45.4%	$1.3M+42.3%	$947K
Gross Profit	N/A	N/A	N/A	$1.3M-98.1%	$68.6M+5755.3%	$1.2M-97.6%	$48.9M+12.9%	$43.3M+224.1%	$13.4M-5.5%	$14.1M-6.8%	$15.2M-3.0%	$15.6M+37.7%	$11.4M+66.6%	$6.8M+176.0%	$2.5M+116.5%	$1.1M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	$7.1M-32.1%	$10.4M-47.3%	$19.8M-27.5%	$27.3M-19.4%	$33.9M-37.2%	$53.9M-25.1%	$72.0M+66.7%	$43.2M+218.9%	$13.6M+201.7%	$4.5M+4089.0%	$107K
SG&A Expenses	$7.2M	$6.9M+44.4%	$4.7M-46.7%	$8.9M-84.3%	$56.7M-29.8%	$80.7M-58.2%	$193.0M+10.8%	$174.1M+50.1%	$116.0M+101.0%	$57.7M+12.4%	$51.3M+78.8%	$28.7M+29.8%	$22.1M+16.4%	$19.0M+35.1%	$14.1M+119.6%	$6.4M
Operating Income	-$4.0M	-$4.4M+28.2%	-$6.1M+28.3%	-$8.5M-815.6%	$1.2M+101.5%	-$79.6M+48.8%	-$155.5M-2.9%	-$151.2M-16.1%	-$130.2M-67.7%	-$77.6M+14.0%	-$90.3M-5.9%	-$85.2M-57.6%	-$54.0M-109.4%	-$25.8M-59.8%	-$16.1M-197.5%	-$5.4M
EBITDA	N/A	-$4.0M+28.5%	-$5.6M+26.3%	-$7.6M-418.8%	$2.4M+103.0%	-$78.8M+48.0%	-$151.5M-1.1%	-$149.8M-15.3%	-$129.9M-67.8%	-$77.4M+14.1%	-$90.1M-5.9%	-$85.1M-57.7%	-$54.0M-109.7%	-$25.8M-60.0%	-$16.1M-199.5%	-$5.4M
Interest Expense	N/A	$8K-20.0%	$10K-96.7%	$300K+50.0%	$200K-99.4%	$32.9M+15.2%	$28.6M+64.4%	$17.4M+271.6%	$4.7M	N/A	N/A	N/A	$1.2M-38.8%	$1.9M0.0%	$1.9M+2859.6%	$64K
Income Tax	N/A	N/A	-$31K+27.9%	-$43K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$217K	-$569K+73.9%	-$2.2M+78.8%	-$10.3M-109.2%	$112.0M+165.0%	-$172.4M+6.1%	-$183.5M-4.2%	-$176.1M-32.8%	-$132.6M-72.4%	-$76.9M+14.4%	-$89.9M-5.6%	-$85.1M-56.9%	-$54.2M-90.8%	-$28.4M	N/A	N/A
EPS (Basic)	N/A	-$0.05+73.7%	-$0.19+80.8%	-$0.99-108.0%	$12.41+157.3%	-$21.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.02	-$0.05+73.7%	-$0.19+80.8%	-$0.99-108.3%	$11.96+155.2%	-$21.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	12M+0.3%	12M+110349.2%	10,441-99.9%	9M+17.7%	8M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K/A	Q3'2410-Q
Revenue	$869K-8.7%	$724K+84.2%	$893K+33.9%	$784K+43.3%	$952K+306.8%	$393K+25.6%	$667K+32.9%	$547K
SG&A Expenses	$1.6M+1.7%	$1.4M+25.2%	$2.7M+959.6%	$1.5M-4.2%	$1.6M-2.0%	$1.1M-18.2%	$255K-82.7%	$1.6M-0.3%
Operating Income	-$816K-17.4%	-$723K+43.6%	-$1.6M-48.2%	-$862K+24.0%	-$695K+75.1%	-$1.3M-12.2%	-$1.0M+35.0%	-$1.1M+36.0%
EBITDA	-$721K-20.4%	-$629K+47.0%	-$1.5M-53.6%	-$766K+26.2%	-$599K+77.0%	-$1.2M-17.5%	-$947K-12.2%	-$1.0M+41.5%
Interest Expense	N/A	N/A	$1K	$3K0.0%	$2K-60.0%	$2K	N/A	$3K-85.0%
Income Tax	N/A	N/A	N/A	N/A	N/A	-$32K	N/A	N/A
Net Income	$155K-71.9%	$95K+114.5%	-$619K-345.6%	$152K+125.0%	$551K+150.6%	-$653K+11.0%	$252K+128.5%	-$609K+82.0%
EPS (Basic)	$0.01-80.0%	$0.01+116.7%	-$0.05-350.0%	$0.01+120.0%	$0.05+155.6%	-$0.060.0%	$0.02+133.3%	-$0.05+84.4%
EPS (Diluted)	$0.01-80.0%	$0.01+116.7%	-$0.05-350.0%	$0.01+120.0%	$0.05+155.6%	-$0.060.0%	$0.02+133.3%	-$0.05+84.4%
Diluted Shares (Avg)	12M+0.6%	11,640+0.8%	N/A	12M+0.4%	12M+0.4%	11,552-99.9%	N/A	12M+7.8%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.

TXMD Balance Sheet

TXMD quarterly balance sheet

Metric	FY2510-K/A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$37.7M-3.0%	$38.8M-10.4%	$43.3M-52.1%	$90.5M-46.6%	$169.5M-6.7%	$181.6M-31.7%	$266.0M+25.5%	$212.0M+48.0%	$143.2M+0.5%	$142.5M+93.2%	$73.7M+24.8%	$59.1M-4.7%	$62.0M+946.5%	$5.9M+311.9%	$1.4M
Current Assets	$14.4M+17.8%	$12.3M+3.9%	$11.8M-78.7%	$55.4M-53.7%	$119.5M-7.0%	$128.4M-38.4%	$208.4M+11.6%	$186.8M+33.8%	$139.6M+0.1%	$139.4M+97.2%	$70.7M+25.7%	$56.2M-5.3%	$59.4M+1181.6%	$4.6M+274.6%	$1.2M
Cash & Equivalents	$7.5M+47.9%	$5.1M+16.9%	$4.3M-91.2%	$49.3M-24.0%	$64.9M-19.4%	$80.5M-50.0%	$160.8M-0.5%	$161.6M+27.1%	$127.1M-3.3%	$131.5M+103.3%	$64.7M+26.0%	$51.4M-5.2%	$54.2M+3388.4%	$1.6M+1128.8%	$126K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	$7.6M-4.6%	$8.0M-32.6%	$11.9M+263.0%	$3.3M+120.0%	$1.5M+38.0%	$1.1M+56.0%	$690K-41.6%	$1.2M+13.3%	$1.0M-35.4%	$1.6M+174.7%	$588K
Accounts Receivable	N/A	N/A	N/A	N/A	$36.2M+11.7%	$32.4M+32.7%	$24.4M+120.5%	$11.1M+155.6%	$4.3M-3.8%	$4.5M+47.6%	$3.0M+41.6%	$2.2M+27.4%	$1.7M+136.7%	$714K+2573.7%	$27K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$10.8M-5.9%	$11.5M-18.3%	$14.0M-74.7%	$55.3M-79.0%	$263.1M-13.9%	$305.6M+19.0%	$256.8M+124.3%	$114.5M+759.2%	$13.3M-11.1%	$15.0M+40.5%	$10.7M-0.2%	$10.7M+46.1%	$7.3M-0.6%	$7.4M+133.6%	$3.2M
Current Liabilities	$4.8M-7.4%	$5.2M-24.6%	$6.9M-85.4%	$46.8M-81.5%	$252.9M+326.9%	$59.2M+11.8%	$53.0M+29.0%	$41.1M+208.4%	$13.3M-11.1%	$15.0M+40.5%	$10.7M-0.2%	$10.7M+46.1%	$7.3M+102.2%	$3.6M+14.9%	$3.2M
Non-Current Liabilities	$6.0M-4.6%	$6.3M-12.3%	$7.2M-15.4%	$8.5M-16.9%	$10.2M-95.9%	$246.4M+20.9%	$203.8M+177.7%	$73.4M	$0	$0	$0	$0	$0-100.0%	$3.7M	$0
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$237.7M+22.1%	$194.6M+165.2%	$73.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$26.9M-1.8%	$27.4M-6.5%	$29.3M-16.7%	$35.1M+137.5%	-$93.6M+24.5%	-$124.0M-1447.7%	$9.2M-90.6%	$97.5M-24.9%	$129.9M+1.9%	$127.5M+102.2%	$63.1M+30.3%	$48.4M-11.5%	$54.7M+3916.7%	-$1.4M+16.3%	-$1.7M
Retained Earnings	-$952.4M-0.1%	-$951.8M-0.2%	-$949.6M-1.1%	-$939.4M+10.7%	-$1.1B-19.6%	-$878.9M-26.4%	-$695.4M-33.9%	-$519.3M-34.3%	-$386.7M-24.8%	-$309.7M-40.9%	-$219.8M-63.1%	-$134.7M-67.3%	-$80.5M-54.5%	-$52.1M-206.7%	-$17.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K/A	Q3'2410-Q
Total Assets	$37.5M-2.5%	$37.6M-1.7%	$37.7M-3.0%	$38.7M	$38.5M-4.0%	$38.2M	$38.8M-10.4%	N/A
Current Assets	$16.1M+19.8%	$15.3M+22.0%	$14.4M+17.8%	$14.5M	$13.5M+13.9%	$12.5M	$12.3M+3.9%	N/A
Cash & Equivalents	$9.2M+51.4%	$8.4M+46.5%	$7.5M+47.9%	$7.1M+41.0%	$6.1M+16.0%	$5.7M+32.4%	$5.1M+16.9%	$5.0M-89.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$10.4M-7.3%	$10.6M-7.7%	$10.8M-5.9%	$11.2M	$11.2M-10.0%	$11.5M	$11.5M-18.3%	N/A
Current Liabilities	$5.0M+7.3%	$4.9M+3.6%	$4.8M-7.4%	$4.9M	$4.7M-19.8%	$4.7M	$5.2M-24.6%	N/A
Non-Current Liabilities	$5.4M-17.6%	$5.7M-15.7%	$6.0M-4.6%	$6.3M	$6.5M-1.4%	$6.8M	$6.3M-12.3%	N/A
Total Equity	$27.1M-0.6%	$27.0M+0.9%	$26.9M-1.8%	$27.4M+1.3%	$27.3M-1.4%	$26.7M-6.7%	$27.4M-6.5%	$27.1M-3.4%
Retained Earnings	-$952.1M0.0%	-$952.3M0.0%	-$952.4M-0.1%	-$951.8M	-$951.9M0.0%	-$952.5M	-$951.8M-0.2%	N/A

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

TXMD Cash Flow Statement

TXMD quarterly cash flow statement

Metric	TTM	FY2510-K/A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$3.1M	$2.5M+109.7%	$1.2M+105.1%	-$23.1M-346.6%	$9.4M+106.6%	-$142.7M+10.5%	-$159.5M+3.8%	-$165.7M-55.1%	-$106.8M-40.3%	-$76.2M-10.1%	-$69.1M+12.5%	-$79.0M-73.6%	-$45.5M-119.2%	-$20.8M-63.0%	-$12.7M-156.5%	-$5.0M
Depreciation & Amortization	N/A	$384K-24.6%	$509K-44.8%	$922K-22.7%	$1.2M+62.1%	$736K-81.9%	$4.1M+192.2%	$1.4M+373.7%	$294K+37.9%	$213K+60.9%	$132K+112.3%	$62K+18.9%	$52K-9.8%	$58K+3.4%	$56K+2.6%	$55K
Stock-Based Compensation	N/A	$75K-71.6%	$264K-79.2%	$1.3M-89.0%	$11.6M-36.2%	$18.1M+69.7%	$10.7M0.0%	$10.7M+23.3%	$8.7M+25.7%	$6.9M-60.4%	$17.4M+142.2%	$7.2M+44.7%	$5.0M+29.3%	$3.8M+105.8%	$1.9M+880.7%	$191K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$34K-83.6%	$207K-91.6%	$2.5M+1028.8%	$217K+251.1%	$62K-84.4%	$396K+139.7%	$165K+433.7%	$31K-24.1%	$41K-38.6%	$66K+130.8%	$29K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$142.7M+10.6%	-$159.7M+5.0%	-$168.2M-57.1%	-$107.0M-40.4%	-$76.2M-9.6%	-$69.5M+12.2%	-$79.2M-73.9%	-$45.6M-118.9%	-$20.8M-62.5%	-$12.8M-156.3%	-$5.0M
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	-$2.2M-39.1%	-$1.6M+93.3%	-$23.9M-11.1%	-$21.5M-2499.2%	-$827K+34.1%	-$1.3M-114.8%	-$584K+3.7%	-$607K-4.0%	-$584K-114.1%	-$273K-624.1%	-$38K
Financing Cash Flow	N/A	N/A	N/A	$3.2M	N/A	$129.6M+60.5%	$80.7M-57.2%	$188.8M+16.0%	$162.8M+124.3%	$72.6M-47.1%	$137.2M+47.6%	$93.0M+114.7%	$43.3M-41.5%	$74.0M+412.5%	$14.4M+206.7%	$4.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K/A	Q3'2410-Q
Operating Cash Flow	$779K+104.5%	$944K+35.1%	$375K+2105.9%	$999K+1507.0%	$381K-73.8%	$699K+405.2%	$17K+100.3%	-$71K+98.8%
Depreciation & Amortization	$95K-1.0%	$94K-1.1%	$97K-3.0%	$96K0.0%	$96K-46.7%	$95K-28.6%	$100K-84.3%	$96K
Stock-Based Compensation	N/A	$2K-91.3%	N/A	N/A	$1K-99.0%	$23K-79.3%	N/A	$33K-83.5%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

TXMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TXMD quarterly financial ratios

Metric	FY2510-K/A	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	100.0%+2.0pp	98.0%+52.5pp	45.5%-29.9pp	75.4%-11.9pp	87.2%+4.2pp	83.0%-1.3pp	84.3%+5.9pp	78.4%+0.8pp	77.6%+2.1pp	75.6%-2.1pp	77.7%+13.0pp	64.7%+10.1pp	54.6%
Operating Margin	-145.3%	-347.1%	-654.6%	1.7%	-3092.8%	-239.8%	-304.6%	-808.9%	-462.7%	-466.3%	-422.9%	-359.6%	-294.1%	-422.9%	-259.9%
Net Margin	-18.8%	-123.8%	-789.4%	160.1%	-6700.9%	-282.9%	-354.8%	-823.7%	-458.5%	-464.3%	-422.4%	-360.8%	-323.8%	N/A	N/A
Return on Equity	-2.1%+5.8pp	-8.0%+27.1pp	-35.1%-353.8pp	318.7%	N/A	N/A	-1914.4%-1778.4pp	-136.0%-76.8pp	-59.2%+11.3pp	-70.5%+64.4pp	-134.9%-22.9pp	-112.0%-60.1pp	-52.0%	N/A	N/A
Return on Assets	-1.5%+4.1pp	-5.6%+18.1pp	-23.7%-147.5pp	123.8%+225.6pp	-101.7%-0.7pp	-101.0%-34.8pp	-66.2%-3.7pp	-62.6%-8.9pp	-53.7%+9.4pp	-63.1%+52.3pp	-115.4%-23.6pp	-91.8%-45.9pp	-45.8%	N/A	N/A
Current Ratio	3.02+0.6x	2.37+0.7x	1.72+0.5x	1.18+0.7x	0.47-1.7x	2.17-1.8x	3.93-0.6x	4.55-5.9x	10.48+1.2x	9.30+2.7x	6.63+1.4x	5.26-2.9x	8.12+6.8x	1.28+0.9x	0.39
Debt-to-Equity	0.400.0x	0.42-0.1x	0.48-1.1x	1.57	N/A	N/A	21.15+20.4x	0.75+0.6x	0.100.0x	0.12-0.1x	0.17-0.1x	0.22+0.1x	0.13	N/A	N/A
Asset Turnover	0.080.0x	0.050.0x	0.03-0.7x	0.77+0.8x	0.02-0.3x	0.36+0.2x	0.19+0.1x	0.080.0x	0.120.0x	0.14-0.1x	0.270.0x	0.25+0.1x	0.14-0.5x	0.64-0.8x	1.45
FCF Margin	N/A	N/A	N/A	N/A	-5547.1%	-246.1%	-338.7%	-664.8%	-454.3%	-359.3%	-393.2%	-303.1%	-237.1%	-335.3%	-239.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K/A	Q3'2410-Q
Operating Margin	-93.9%-20.9pp	-99.9%	-173.8%	-109.9%	-73.0%	-325.9%	-157.0%	-207.3%
Net Margin	17.8%-40.0pp	13.1%	-69.3%-107.1pp	19.4%	57.9%	-166.2%	37.8%	-111.3%
Return on Equity	0.6%-1.4pp	0.4%+2.8pp	-2.3%-3.2pp	0.5%+2.8pp	2.0%+6.0pp	-2.4%+0.1pp	0.9%+3.9pp	-2.3%+9.8pp
Return on Assets	0.4%-1.0pp	0.3%+2.0pp	-1.6%-2.3pp	0.4%	1.4%+4.1pp	-1.7%	0.7%+2.7pp	N/A
Current Ratio	3.22+0.3x	3.11+0.5x	3.02+0.6x	2.93	2.89+0.9x	2.64	2.37+0.7x	N/A
Debt-to-Equity	0.380.0x	0.390.0x	0.400.0x	0.41	0.410.0x	0.43	0.42-0.1x	N/A
Asset Turnover	0.020.0x	0.020.0x	0.020.0x	0.02	0.020.0x	0.01	0.020.0x	N/A

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
TherapeuticsMD, Inc. TXMD	FY2025	$3.0M	-$569K	-18.8%	$23.8M	63/100
Flora Growth Corp. FLGC	FY2025	$35.7M	-$119.7M	N/A	$21.6M	32/100
Gelteq Limited GELS	FY2025	N/A	-$6.6M	N/A	$5.9M	—
Biofrontera Inc. BFRI	FY2025	$41.7M	-$10.5M	-25.3%	$13.6M	39/100
AYTU BioPharma, Inc. AYTU	FY2026	$57.6M	-$14.3M	-24.8%	$22.3M	47/100

Where TherapeuticsMD, Inc. Ranks

Frequently Asked Questions

What is TherapeuticsMD, Inc.'s annual revenue?

TherapeuticsMD, Inc. (TXMD) reported $3.0M in total revenue for fiscal year 2025. This represents a 71.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is TherapeuticsMD, Inc.'s revenue growing?

TherapeuticsMD, Inc. (TXMD) revenue grew by 71.6% year-over-year, from $1.8M to $3.0M in fiscal year 2025.

Is TherapeuticsMD, Inc. profitable?

No, TherapeuticsMD, Inc. (TXMD) reported a net income of -$569K in fiscal year 2025, with a net profit margin of -18.8%.

What is TherapeuticsMD, Inc.'s EBITDA?

TherapeuticsMD, Inc. (TXMD) had EBITDA of -$4.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is TherapeuticsMD, Inc.'s net profit margin?

TherapeuticsMD, Inc. (TXMD) had a net profit margin of -18.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is TherapeuticsMD, Inc.'s return on equity (ROE)?

TherapeuticsMD, Inc. (TXMD) has a return on equity of -2.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is TherapeuticsMD, Inc.'s operating cash flow?

TherapeuticsMD, Inc. (TXMD) generated $2.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are TherapeuticsMD, Inc.'s total assets?

TherapeuticsMD, Inc. (TXMD) had $37.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does TherapeuticsMD, Inc. have outstanding?

TherapeuticsMD, Inc. (TXMD) had 12M shares outstanding as of fiscal year 2025.

What is TherapeuticsMD, Inc.'s current ratio?

TherapeuticsMD, Inc. (TXMD) had a current ratio of 3.02 as of fiscal year 2025, which is generally considered healthy.

What is TherapeuticsMD, Inc.'s debt-to-equity ratio?

TherapeuticsMD, Inc. (TXMD) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is TherapeuticsMD, Inc.'s return on assets (ROA)?

TherapeuticsMD, Inc. (TXMD) had a return on assets of -1.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is TherapeuticsMD, Inc.'s P/E ratio?

TherapeuticsMD, Inc. (TXMD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $23.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is TherapeuticsMD, Inc.'s price-to-sales ratio?

TherapeuticsMD, Inc. (TXMD) trades at 7.3x sales, its market capitalization divided by revenue of $3.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $23.8M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is TherapeuticsMD, Inc.'s Altman Z-Score?

TherapeuticsMD, Inc. (TXMD) has an Altman Z-Score of -34.08, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is TherapeuticsMD, Inc.'s Piotroski F-Score?

TherapeuticsMD, Inc. (TXMD) has a Piotroski F-Score of 6 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are TherapeuticsMD, Inc.'s earnings high quality?

TherapeuticsMD, Inc. (TXMD) reported a net loss of $569K while generating $2.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can TherapeuticsMD, Inc. cover its interest payments?

TherapeuticsMD, Inc. (TXMD) reported an operating loss of $4.4M against $8K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is TherapeuticsMD, Inc.?

TherapeuticsMD, Inc. (TXMD) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.